Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUSS trial of intratracheal budesonide plus surfactant for prevention of bronchopulmonary dysplasia
ACTRN12617000322336Phase 3Active, not recruiting
- Sponsor
- Melbourne Children's Trials Centre
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) and respiratory distress syndrome (RDS) comparing Budesonide + Curosurf with Curosurf alone (2 arms). Primary endpoint: Survival free of physiological bronchopulmonary dysplasia. Started Jan 2018; status: active, not recruiting.
02
Drugs
budesonidePoractant alfa
03
Conditions
bronchopulmonary dysplasia (BPD)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ACTRN12617000322336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000322336.